-DOCSTART- -X- O
Monoclonal -X- _ O
antibodies -X- _ O
( -X- _ O
mAbs -X- _ O
) -X- _ O
have -X- _ O
become -X- _ O
increasingly -X- _ O
important -X- _ O
as -X- _ O
human -X- _ O
therapeutic -X- _ O
agents. -X- _ O
Yet -X- _ O
, -X- _ O
current -X- _ O
research -X- _ O
concentrates -X- _ O
on -X- _ O
technology -X- _ O
itself -X- _ O
and -X- _ O
pays -X- _ O
attention -X- _ O
to -X- _ O
developed -X- _ O
countries. -X- _ O
This -X- _ O
paper -X- _ O
aims -X- _ O
to -X- _ O
provide -X- _ O
a -X- _ O
comprehensive -X- _ O
review -X- _ O
of -X- _ O
mAbs -X- _ B-Intervention
development -X- _ I-Intervention
in -X- _ O
China -X- _ B-Patient
through -X- _ O
systematic -X- _ O
analysis -X- _ O
of -X- _ O
drug -X- _ O
registry -X- _ O
, -X- _ O
patent -X- _ O
applications -X- _ O
, -X- _ O
clinical -X- _ O
trials -X- _ O
, -X- _ O
academic -X- _ O
publication -X- _ O
, -X- _ O
and -X- _ O
ongoing -X- _ O
R -X- _ O
& -X- _ O
D -X- _ O
projects. -X- _ O
The -X- _ O
trends -X- _ O
in -X- _ O
therapeutic -X- _ O
areas -X- _ O
and -X- _ O
industrialization -X- _ O
process -X- _ O
are -X- _ O
also -X- _ O
highlighted. -X- _ O
Development -X- _ B-Outcome
and -X- _ I-Outcome
research -X- _ I-Outcome
trends -X- _ I-Outcome
of -X- _ I-Outcome
mAbs -X- _ I-Outcome
are -X- _ I-Outcome
analyzed -X- _ I-Outcome
to -X- _ I-Outcome
provide -X- _ I-Outcome
a -X- _ I-Outcome
future -X- _ I-Outcome
perspective -X- _ I-Outcome
of -X- _ I-Outcome
mAbs -X- _ I-Outcome
as -X- _ I-Outcome
therapeutic -X- _ I-Outcome
agents -X- _ I-Outcome
in -X- _ I-Outcome
China -X- _ I-Outcome
. -X- _ O

